News and Announcements
Vortex Fluidic Device set to make First Graphene (ASX: FGR) leader in the industry
- Published June 27, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- First Graphene Limited and Flinders University’s Nanoscale Science and Technology launch new associate company, 2D Fluidics Pty Ltd.
- 2D Fluidics will commercialise Vortex Fluidic Device (VFD).
- VFD allows the production of materials such as Graphene and sliced carbon nanotubes.
First Graphene Limited has announced the launch of its 50% owned associate company, 2D Fluidics Pty Ltd. The company was developed in collaboration with Flinders University Institute for NanoScale Science and Technology. The establishment of 2D Fluidics is to commercialise the Vortex Fluidic Device (VFD) to produce a range of materials and comprises of two patents around the production of carbon nanomaterials. The VFD was created by Flinders University’s, Professor Colin Raston in South Australia.
First Graphene Limited produce high-quality graphene from Sri Lankan vein graphite and this new position will position them as the leading graphene company.
The VFD represents the development of a new chemical processing space. It provides a new clean approach to creating new materials such as graphene and sliced carbon nanotubes. The clean approach of not having to use harsh or toxic chemicals in the manufacturing process will reduce costs and improve the efficiency of manufacturing these new carbon materials. 2D Fluidics will both manufacture the VFD and use the VFD to prepare material for commercial sales. VFD is forecasted to become a research tool for university worldwide bringing strong revenue to the new company.
About First Graphene Limited (ASX: FGR)
First Graphene is an advanced materials company seeking to position itself in the lowest cost quartile of global graphene suppliers. It has developed an environmentally sound and safe method of converting its supplies of ultra-high grade graphite into the lowest cost highest quality graphene, in bulk quantities.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
